Caladrius Biosciences (Nasdaq:CLBS) a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces financial results for the three and twelve months ended December 31, 2017 and provides a business update. As quoted in the press release: “The past months have been especially productive as we made much progress advancing and …

As quoted in the press release:

“The past months have been especially productive as we made much progress advancing and expanding our clinical development pipeline,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “We were particularly pleased to acquire the late-stage asset from Shire’s CD34 cell therapy program for the treatment of refractory angina. In addition to adding a potentially late-stage product candidate that is complementary to our current pipeline in ischemic repair, this program represents a large potential commercial opportunity as refractory angina afflicts approximately one million people in the U.S. alone, with an incidence rate of 50,000 to 100,000 annually.

Click here to read the full press release.